MAIA starts Romania enrollment for Phase 2 THIO-101 Part C; 38% ORR vs standard 6% cited

MAIA Biotechnology, Inc.

CEO presented at Smart Diaspora 2025; Romania begins screening patients for THIO-101 Part C.
Observed 38% overall response rate vs current third-line NSCLC treatments with ~6% response rate.
FDA Fast Track Designation for ateganosine received in July 2025, supports accelerated approval path.
Third-line NSCLC patients resistant to chemo and immunotherapy are target population.
Investigator Tudor Ciuleanu, MD, PhD, is key opinion leader in Eastern Europe.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.